<div id="readability-page-1"><div><p><span>Ucb SA </span><span>:</span></p><ul><li>POSITIVE RESULTS FROM GEMZ PHASE 3 STUDY</li><li>FENFLURAMINE SIGNIFICANTLY REDUCES COUNTABLE MOTOR SEIZURE FREQUENCY IN CDKL5 DEFICIENCY DISORDER</li><li>FENFLURAMINE WAS GENERALLY WELL TOLERATED, WITH NO NEW SAFETY SIGNALS IDENTIFIED</li><li>PLANS TO SUBMIT FOR REGULATORY APPROVAL OF FENFLURAMINE  AS SOON AS POSSIBLE</li></ul></div></div>

UCBJY

<p>Ucb SA :POSITIVE RESULTS FROM GEMZ PHASE 3 STUDYFENFLURAMINE SIGNIFICANTLY REDUCES COUNTABLE MOTOR SEIZURE FREQUENCY IN CDKL5 DEFICIENCY DISORDERFENFLURAMINE WAS GENERALLY WELL TOLERATED, WITH NO NEW SAFETY SIGNALS IDENTIFIEDPLANS TO SUBMIT FOR REGULATORY APPROVAL OF FENFLURAMINE AS SOON AS POSSIBLE</p>

UCB Reports Positive Results From Gemz Phase 3 Study